Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 14, 2019
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , July 23, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Announces New Leadership Appointments
Global Clinical and Medical Affairs Veteran, Theresa G.H. Heah , M.D., M.B.A., to Join AGTC as Chief Medical Officer Brian Krex Named General Counsel GAINESVILLE, Fla. and CAMBRIDGE, Mass. , June 25, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology
View HTML
Toggle Summary AGTC to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference on June 25, 2019
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , June 18, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 07, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 7, 2019
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Reaching Enrollment Milestones in Phase 1/2 Clinical Trials
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2018
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 7, 2019
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration
- Results from XLRS study support general safety and tolerability of AGTC’s gene delivery platform but did not demonstrate signs of clinical activity at interim six-month time point - -  AGTC to regain rights to five clinical and preclinical development programs; Biogen terminates collaboration
View HTML
Visionary science for life changing cures.